C Cost Minimization Analysis (CMA) Penggunaan Obat Amlodipine Dan Captopril Pada Pasien Hipertensi di RSUD Sultan Suriansyah Banjarmasin

Siti Azizah; Iwan Yuwindry; Tri Sulapmi D. Ikeh; Melviani Melviani

doi:10.33859/jpcs.v5i1.660

Authors

Siti Azizah Universitas Sari Mulia Banjarmasin
Iwan Yuwindry Sari Mulia University
Tri Sulapmi D. Ikeh Sari Mulia University
Melviani Melviani Sari Mulia University

DOI:

https://doi.org/10.33859/jpcs.v5i1.660

Keywords:

Amlodipine, Hypertension, CMA, Captopril

Abstract

Background: Hypertension is one of the serious problems currently known as the silent killer, and the prevalence throughout the world of hypertension is very high, which has the potential to increase the medical costs that must be borne by patients, therefore minimal treatment of hypertension can reduce the high incidence of hypertension.
Objective: The aim of this study was to determine the most cost-minimum costs of using the drugs amlodipine and captopril in hypertensive patients in the outpatient installation of Sultan Suriansyah Hospital, Banjarmasin.
Methods: This research was conducted using an observational analytical method with a cross sectional design. Data collection was carried out using medical records and details of drug costs in the pharmacy department, and receipts in the finance department for hypertensive patients in outpatient installations who received amlodipine and captopril treatment at Sultan Suriansyah Hospital, Banjarmasin. The sample used was 38 patients. The cost components collected are direct medical costs including the total costs for antihypertensive treatment, costs for treating comorbidities, administration costs and consultation costs.
Results: The results of this research showed that the average total direct medical costs for the amlodipine group were Rp.98.491 and the captopril group was Rp.109.613.
Conclusion: Based on cost minimization analysis calculations, the 2 antihypertensive drug therapies that are cost minimized are amlodipine 10 mg tablets compared to captopril 25 mg tablets.

References

BNF. (2019). British National Formulary, Ed. 76th . British National Formulary, Ed. 76th ., 290.

Brunton, L. L., Dandan, R. H., & Knollmann, B. C. (2018). The Pharmacological Basis Of Therapeutics (Thirteenth).

Dewan Perwakilan Rakyat RI. (2023). Undang-Undang Republik Indonesia Nomor 17 Tahun 2023 Tentang Kesehatan. Undang-Undang, 187315, 1–300.

Dewi, M. I. K., Prabowo, W. C., & Rusli, R. (2019). Analisis Biaya Minimal Penggunaan Antihipertensi Di Rumah Sakit Umum Daerah Kota Bontang. Proceeding of Mulawarman Pharmaceuticals Conferences, 9, 27–31. https://doi.org/10.25026/mpc.v9i1.338

Dinkes, D. K. M. (2020). Laporan Kinerjaa Dinas Kesehatan Provinsi Kalimantan Selatan.

Kemenkes RI. (2019). Pedoman Pelayanan Kefarmasian Pada Hipertensi.pdf.

Khoiriyah, S. D., & Lestari, K. (2019). Review Artikel: Kajian Farmakoekonomi Yang Mendasari Pemilihan Pengobatan Di Indonesia. MPI (Media Pharmaceutica Indonesiana), 16(3). https://doi.org/10.24123/mpi.v2i2.1391

Mazaya, S.S., Rifkia, V., & Chairani, A (2020). Perbandingan Penurunan Tekanan Darah Pasien Hipertensi Intradialisis Dengan Obat Antihipertensi Amlodipin dan Kaptopril di RS Bhayangkara TK. I R. Said Sukanto. Jurnal Farmasi Udayana, 9(2), 83. https://doi.org/10.24843/jfu.2020.v09.i02.p03

Merliana, H., & Sjaaf, A. C. (2017). Analisis Minimisasi Biaya Amlodipin Generik dan Bermerk pada Pengobatan Hipertensi di RS X Pekanbaru Tahun 2015. Jurnal Ekonomi Kesehatan Indonesia, 1(3), 114–119. https://doi.org/10.7454/eki.v1i3.1775

Muna, N. (2022). Cost Minimization Analysis (CMA) Penggunaan Obat Captopril Dan Lisinopril Pada Pasien Hipertensi Di Rsud Sultan Suriansyah Banjarmasin.

Perhimpunan Dokter Hipertensi Indonesia. (2019). Konsensus Penatalaksanaan Hipertensi 2019. Indonesian Society Hipertensi Indonesia, 1–90.

Rahayu, D., Kusuma, N., Amarullah, A., Rahmawati, D., Kesehatan, F. I., Anwar, U., & Sidoarjo, M. (2023). Cost Minimization Analysis Pasien JKN Rawat Jalan Penyakit Hipertensi di RS “ X ” Kota Surabaya. Journal of Health Management Research, 2(2), 46–55.

Rai, M., & Goyal, R. (2018). Chapter 33 - Pharmacoeconomics in Healthcare. Pharmaceutical Medicine and Translational Clinikal Research. https://doi.org/https://doi.org/10.1016/B978-0-12-802103-3.00034-1

Riannur, T., Eka, S. S., & Sentat, T. (2021). Analisis Biaya Minimal Candesartan Dibandingkan Amlodipin Pada Pasien Hipertensi Rawat Jalan Di Rs “X” Kota Samarinda. Prosiding Sekolah Tinggi Ilmu Kesehatan, 94–103.

Utari, A. B., & Rochmah, T. N. (2018). Cost of Hypertension Disease in Kediri Regency. January 2017, 272–276. https://doi.org/10.5220/0007028702720276